Use of immunosuppressants/immunomodulators in autoimmune/inflammatory dermatologic diseases during COVID-19 pandemic—General recommendation based on available evidence

Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS‐CoV‐2

“… 12 However, if patients are positive for SARS‐CoV‐2, these drugs should be temporarily withdrawn, after considering the severity of AIBDs, past medical history, comorbidities, age, and severity of COVID‐19, except corticosteroids, which should be reduced gradually to at least 7.5–10 mg/day to avoid abrupt termination or considerable dose reduction. 11 , 13 , 14 Moreover, some experts found that the low‐dose systemic dexamethasone decreased the mortality rate in COVID‐19 patients who were receiving either invasive mechanical ventilation or oxygen alone at randomization. 15 …”